KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) EBITDA (2016 - 2025)

Historic EBITDA for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $167.6 million.

  • West Pharmaceutical Services' EBITDA rose 390.58% to $167.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $587.9 million, marking a year-over-year increase of 292.37%. This contributed to the annual value of $569.9 million for FY2024, which is 1569.53% down from last year.
  • Latest data reveals that West Pharmaceutical Services reported EBITDA of $167.6 million as of Q3 2025, which was up 390.58% from $153.7 million recorded in Q2 2025.
  • West Pharmaceutical Services' 5-year EBITDA high stood at $228.4 million for Q2 2022, and its period low was $107.0 million during Q1 2025.
  • Over the past 5 years, West Pharmaceutical Services' median EBITDA value was $167.6 million (recorded in 2025), while the average stood at $166.3 million.
  • In the last 5 years, West Pharmaceutical Services' EBITDA soared by 10395.75% in 2021 and then tumbled by 3084.93% in 2024.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' EBITDA stood at $184.0 million in 2021, then dropped by 29.51% to $129.7 million in 2022, then rose by 24.06% to $160.9 million in 2023, then decreased by 0.81% to $159.6 million in 2024, then rose by 5.01% to $167.6 million in 2025.
  • Its EBITDA stands at $167.6 million for Q3 2025, versus $153.7 million for Q2 2025 and $107.0 million for Q1 2025.